IntrinsiQ Marks Record Growth of Clinical Software User Base in Q3 2007
Waltham, Mass. (Nov. 28, 2007) — Oncologists nationwide are increasingly choosing IntelliDose® -- the industry’s de facto standard for capturing vital chemotherapy dosage and treatment information -- as their primary solution for driving clinical best practice.
As these physicians move from paper to electronic processes, they’re driving record growth for IntrinsiQ, LLC and its flagship oncology electronic health record (EHR) software, IntelliDose. The IntelliDose customer base expanded by 10 percent in the past 90 days, and continued its 100 percent customer renewal rate.
The newest IntelliDose customers include Shands Jacksonville Medical Center, a University of Florida Health Science Center affiliate; Decatur Memorial Hospital, Central Illinois’ regional medical center; and Medical Oncology and Hematology Associates, a Des Moines oncology practice. They join more than 700 oncologists at leading hospitals, health networks and private practices who rely on IntelliDose to ensure patient safety and improve their business performance.
These practitioners collectively treat more than 19,500 patients each month – creating the largest base of actual and real-time oncology treatment decisions.
“Cancer chemotherapy is a complex field of medicine with significant risks from medical errors,” said Simeon A. Schwartz, M.D., president of White Plains, NY-based Westchester Medical Group. “Physicians need to implement automated systems for safety and accuracy – making tools like IntelliDose an absolute necessity.”
IntelliDose integrates with all of the leading Health Information Systems (HIS), Electronic Medical Record (EMR) and Practice Management (PM) systems – eliminating the overhead and risks of error of manual chemotherapy order entry. Because it is fully integrated with patients’ most recent lab work, it automatically produces the most accurate, verified medication orders. This streamlines delivery of even the most complex treatment, and provides critical assurance that the practice complies with the most stringent safety standards.
“Oncologists are under tremendous pressure – and their priority is delivering outstanding patient care,” said Bill Wisotzkey, general manager of IntelliDose at IntrinsiQ. “We take the worry out of the picture, by providing complete, accurate information about every aspect of treatment. This improves overall clinic performance, and puts best-in-class medical care back at the heart of what our customers deliver.”
IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s market leading software application, IntelliDose®, captures the treatment decisions and details from more than 700 physicians, for more than 19,500 unique patients, and regarding more than 128,000 drug administrations. IntelliDose gives oncology physicians a clinical information system that ensures patient safety though automation and standards built specifically to meet the needs of a specific practice, saving staff time, maximizing reimbursement and reducing operating costs. For more information, please visit www.intrinsiq.com.
Bill Wisotzkey
(781) 434-3324
bill.wisotzkey@intrinsiq.com
Megan Boyaval
(617) 969-9192
mboyaval@corporateink.com